Literature DB >> 15137062

Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.

Mary Karst1, Genevieve Gorny, Rachelle J Sells Galvin, Merry Jo Oursler.   

Abstract

To better understand the complex roles of transforming growth factor-beta (TGF-beta) in bone metabolism, we examined the impact of a range of TGF-beta concentrations on osteoclast differentiation. In co-cultures of support cells and spleen or marrow osteoclast precursors, low TGF-beta concentrations stimulated while high concentrations inhibited differentiation. We investigated the influences of TGF-beta on macrophage colony stimulating factor (M-CSF), receptor activator of NF-kappaB ligand (RANKL), and osteoprotegerin (OPG) expression and found a dose dependent inhibition of M-CSF expression. RANKL expression was elevated at low TGF-beta concentrations with a less dramatic increase in OPG. Addition of OPG blocked differentiation at the stimulatory TGF-beta dose. Thus, low TGF-beta concentrations elevated the RANKL/OPG ratio while high concentrations did not, supporting that, at low TGF-beta concentrations, there is sufficient M-CSF and a high RANKL/OPG ratio to stimulate differentiation. At high TGF-beta concentrations, the RANKL/OPG ratio and M-CSF expression were both repressed and there was no differentiation. We examined whether TGF-beta-mediated repression of osteoclasts differentiation is due to these changes by adding M-CSF and/or RANKL and did not observe any impact on differentiation repression. We studied direct TGF-beta impacts on osteoclast precursors by culturing spleen or marrow cells with M-CSF and RANKL. TGF-beta treatment dose-dependently stimulated osteoclast differentiation. These data indicate that low TGF-beta levels stimulate osteoclast differentiation by impacting the RANKL/OPG ratio while high TGF-beta levels repress osteoclast differentiation by multiple avenues including mechanisms independent of the RANKL/OPG ratio or M-CSF expression regulation. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15137062      PMCID: PMC4547836          DOI: 10.1002/jcp.20036

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  33 in total

Review 1.  The molecular basis of osteoclast differentiation and activation.

Authors:  T Suda; K Kobayashi; E Jimi; N Udagawa; N Takahashi
Journal:  Novartis Found Symp       Date:  2001

2.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; H Tanaka; T Sasaki; T Nishihara; T Koga; T J Martin; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 3.  Minireview: the OPG/RANKL/RANK system.

Authors:  S Khosla
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

4.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  The TGF-beta family of growth and differentiation factors.

Authors:  J Massagué
Journal:  Cell       Date:  1987-05-22       Impact factor: 41.582

6.  Membrane binding characteristics of two forms of transforming growth factor-beta.

Authors:  P R Segarini; A B Roberts; D M Rosen; S M Seyedin
Journal:  J Biol Chem       Date:  1987-10-25       Impact factor: 5.157

7.  Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells.

Authors:  N Takahashi; N Udagawa; T Akatsu; H Tanaka; Y Isogai; T Suda
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

8.  Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.

Authors:  J M Quinn; K Itoh; N Udagawa; K Hausler; H Yasuda; N Shima; A Mizuno; K Higashio; N Takahashi; T Suda; T J Martin; M T Gillespie
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

9.  Transforming growth factor beta2, but not beta1 and beta3, is critical for early rat lung branching.

Authors:  J Liu; I Tseu; J Wang; K Tanswell; M Post
Journal:  Dev Dyn       Date:  2000-04       Impact factor: 3.780

10.  Comparison of the biological actions of TGF beta-1 and TGF beta-2: differential activity in endothelial cells.

Authors:  J C Jennings; S Mohan; T A Linkhart; R Widstrom; D J Baylink
Journal:  J Cell Physiol       Date:  1988-10       Impact factor: 6.384

View more
  61 in total

1.  Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGF{beta} stimulation of RANKL production.

Authors:  Harikiran Nistala; Sui Lee-Arteaga; Silvia Smaldone; Gabriella Siciliano; Francesco Ramirez
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

2.  Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling.

Authors:  Clarissa S Craft; Wei Zou; Marcus Watkins; Susan Grimston; Michael D Brodt; Thomas J Broekelmann; Justin S Weinbaum; Steven L Teitelbaum; Richard A Pierce; Roberto Civitelli; Matthew J Silva; Robert P Mecham
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

3.  TGF-β mediates suppression of adipogenesis by estradiol through connective tissue growth factor induction.

Authors:  Ashok Kumar; Ming Ruan; Kari Clifton; Farhan Syed; Sundeep Khosla; Merry Jo Oursler
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

4.  Identification of novel RANK polymorphisms and their putative association with low BMD among postmenopausal women.

Authors:  J-M Koh; B L Park; D J Kim; G S Kim; H S Cheong; T-H Kim; J-M Hong; H-I Shin; E K Park; S-Y Kim; H D Shin
Journal:  Osteoporos Int       Date:  2006-11-18       Impact factor: 4.507

5.  TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.

Authors:  Anne Gingery; Elizabeth W Bradley; Larry Pederson; Ming Ruan; Nikki J Horwood; Merry Jo Oursler
Journal:  Exp Cell Res       Date:  2008-06-13       Impact factor: 3.905

Review 6.  Regulation of postnatal bone homeostasis by TGFβ.

Authors:  Simon Y Tang; Tamara Alliston
Journal:  Bonekey Rep       Date:  2013-01-09

7.  Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.

Authors:  Larry Pederson; Ming Ruan; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

8.  Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization.

Authors:  Kuniaki Ota; Patrick Quint; Ming Ruan; Larry Pederson; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  J Cell Biochem       Date:  2013-08       Impact factor: 4.429

9.  PAK1 is a novel MEK-independent raf target controlling expression of the IAP survivin in M-CSF-mediated osteoclast survival.

Authors:  Elizabeth W Bradley; Ming M Ruan; Merry J Oursler
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

10.  An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3.

Authors:  Robert D Nerenz; Melissa L Martowicz; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2008-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.